Aaron Miller, M.D..
Dr. Miller is Professor of Neurology and Medical Director Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY.
Within the past 12 months, Dr. Miller has received research support from Acorda, Novartis, Genentech, Genzyme, Sanofi-Avenits, Biogen Idec, Roche and Questor and been a consultant to Genzyme, Sanofi-Aventis, Biogen Idec, Glaxo Smith Kline, EMD Serono, Novartis, Accorda, Nuron Biotech, Accordant Health Services and Teva.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.
This activity is certified for neurology and primary care (internal medicine, family practice and women’s health) and for all health professionals interested in the treatment of RRMS.
This activity is made possible by an unrestricted educational grant from Biogen Idec.
Release Date: 06/02/2014
Termination Date: 06/01/2017
Estimated time to complete: 1 hour(s).
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Discuss the pathogenesis, epidemiology, symptoms and diagnosis of RRMS
- Select and prescribe appropriate pharmaceuticals for patients with RRMS
- Discuss the role of risk stratification (e.g., serum JC virus antibody status) in the therapeutic management of RRMS
- Describe on-going clinical trials for emerging RRMS therapies/strategies and evaluate data on safety, efficacy and management of side effects.